FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975207029> ?p ?o ?g. }

• W1975207029 endingPage "222" @default.
• W1975207029 startingPage "216" @default.
• W1975207029 abstract "Vasoactive intestinal peptide (VIP) is a pleiotropic neuropeptide with potent anti-inflammatory properties, and its receptor, VPAC1, mediates most of the anti-inflammatory effects of VIP. Diabetes mellitus is characterized by increased oxidation and inflammation due to persistent hyperglycemia. This research was performed to investigate the effects of VIP and a VPAC1 agonist on streptozotocin (STZ)-induced type 1 diabetic mice. Intraperitoneal injection of VIP and VPAC1 agonist (50nmol/kg/day in saline) over a 28-day period (1) decreased food intake, (2) increased body weight, (3) improved visceral index, (4) increased the fasting plasma insulin levels, (5) decreased the fasting plasma glucose, (6) improved the glucose tolerance, (7) decreased pancreas H(2)O(2) and malondialdehyde (MDA) and (8) increased total antioxidant activity (T-AOC) in the liver, spleen and pancreas. The results of histopathological and immunohistochemical analysis showed that VIP and the VPAC1 agonist improved the structure and cellularity of islets and ameliorated the insulin-secreting activity of islets. Additionally, administration of VIP or the VPAC1 agonist not only significantly decreased the plasma TNFα and CRP and promoted IL-10 in diabetic mice but also blocked the increased NF-κB activity of pancreatic tissue in diabetic mice. Furthermore, the VPAC1 agonist displayed stronger effects than VIP. These results show that both VIP and VPAC1 agonist ameliorated STZ-induced diabetes and protected mice against oxidative stress and inflammation associated diabetes, with VPAC1 being the receptor most responsible for these positive effects in diabetic mice." @default.
• W1975207029 created "2016-06-24" @default.
• W1975207029 creator A5002323402 @default.
• W1975207029 creator A5005425564 @default.
• W1975207029 creator A5007913179 @default.
• W1975207029 creator A5039085310 @default.
• W1975207029 creator A5090427100 @default.
• W1975207029 date "2011-02-01" @default.
• W1975207029 modified "2023-10-16" @default.
• W1975207029 title "Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice" @default.
• W1975207029 cites W1496633211 @default.
• W1975207029 cites W1557599311 @default.
• W1975207029 cites W1866929957 @default.
• W1975207029 cites W1976153774 @default.
• W1975207029 cites W1979339435 @default.
• W1975207029 cites W1998899790 @default.
• W1975207029 cites W2000998212 @default.
• W1975207029 cites W2003450091 @default.
• W1975207029 cites W2014223279 @default.
• W1975207029 cites W2016813845 @default.
• W1975207029 cites W2020246061 @default.
• W1975207029 cites W2021613066 @default.
• W1975207029 cites W2038039362 @default.
• W1975207029 cites W2038581703 @default.
• W1975207029 cites W2039578759 @default.
• W1975207029 cites W2039796762 @default.
• W1975207029 cites W2040166628 @default.
• W1975207029 cites W2051941603 @default.
• W1975207029 cites W2054408979 @default.
• W1975207029 cites W2056379818 @default.
• W1975207029 cites W2061549656 @default.
• W1975207029 cites W2069206441 @default.
• W1975207029 cites W2069889415 @default.
• W1975207029 cites W2078816353 @default.
• W1975207029 cites W2091026717 @default.
• W1975207029 cites W2093528009 @default.
• W1975207029 cites W2093818683 @default.
• W1975207029 cites W2097585375 @default.
• W1975207029 cites W2104130513 @default.
• W1975207029 cites W2106400751 @default.
• W1975207029 cites W2124098523 @default.
• W1975207029 cites W2132316522 @default.
• W1975207029 cites W2150910700 @default.
• W1975207029 cites W2152740168 @default.
• W1975207029 cites W2154166421 @default.
• W1975207029 cites W2165644319 @default.
• W1975207029 cites W2168189794 @default.
• W1975207029 cites W4313376917 @default.
• W1975207029 doi "https://doi.org/10.1016/j.peptides.2010.11.017" @default.
• W1975207029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21129425" @default.
• W1975207029 hasPublicationYear "2011" @default.
• W1975207029 type Work @default.
• W1975207029 sameAs 1975207029 @default.
• W1975207029 citedByCount "29" @default.
• W1975207029 countsByYear W19752070292012 @default.
• W1975207029 countsByYear W19752070292013 @default.
• W1975207029 countsByYear W19752070292015 @default.
• W1975207029 countsByYear W19752070292016 @default.
• W1975207029 countsByYear W19752070292017 @default.
• W1975207029 countsByYear W19752070292018 @default.
• W1975207029 countsByYear W19752070292019 @default.
• W1975207029 countsByYear W19752070292021 @default.
• W1975207029 countsByYear W19752070292022 @default.
• W1975207029 countsByYear W19752070292023 @default.
• W1975207029 crossrefType "journal-article" @default.
• W1975207029 hasAuthorship W1975207029A5002323402 @default.
• W1975207029 hasAuthorship W1975207029A5005425564 @default.
• W1975207029 hasAuthorship W1975207029A5007913179 @default.
• W1975207029 hasAuthorship W1975207029A5039085310 @default.
• W1975207029 hasAuthorship W1975207029A5090427100 @default.
• W1975207029 hasConcept C118303440 @default.
• W1975207029 hasConcept C126322002 @default.
• W1975207029 hasConcept C134018914 @default.
• W1975207029 hasConcept C170493617 @default.
• W1975207029 hasConcept C2776151105 @default.
• W1975207029 hasConcept C2778401633 @default.
• W1975207029 hasConcept C2778764654 @default.
• W1975207029 hasConcept C2778938600 @default.
• W1975207029 hasConcept C2779280383 @default.
• W1975207029 hasConcept C2779306644 @default.
• W1975207029 hasConcept C555293320 @default.
• W1975207029 hasConcept C71924100 @default.
• W1975207029 hasConcept C8330315 @default.
• W1975207029 hasConceptScore W1975207029C118303440 @default.
• W1975207029 hasConceptScore W1975207029C126322002 @default.
• W1975207029 hasConceptScore W1975207029C134018914 @default.
• W1975207029 hasConceptScore W1975207029C170493617 @default.
• W1975207029 hasConceptScore W1975207029C2776151105 @default.
• W1975207029 hasConceptScore W1975207029C2778401633 @default.
• W1975207029 hasConceptScore W1975207029C2778764654 @default.
• W1975207029 hasConceptScore W1975207029C2778938600 @default.
• W1975207029 hasConceptScore W1975207029C2779280383 @default.
• W1975207029 hasConceptScore W1975207029C2779306644 @default.
• W1975207029 hasConceptScore W1975207029C555293320 @default.
• W1975207029 hasConceptScore W1975207029C71924100 @default.
• W1975207029 hasConceptScore W1975207029C8330315 @default.
• W1975207029 hasIssue "2" @default.
• W1975207029 hasLocation W19752070291 @default.

• next